Review ArticleContinuing Education
PET Imaging of Proliferation with Pyrimidines
Omid S. Tehrani and Anthony F. Shields
Journal of Nuclear Medicine June 2013, 54 (6) 903-912; DOI: https://doi.org/10.2967/jnumed.112.112201
Omid S. Tehrani
Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan
Anthony F. Shields
Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan
This article has a correction. Please see:
In this issue
Journal of Nuclear Medicine
Vol. 54, Issue 6
June 1, 2013
PET Imaging of Proliferation with Pyrimidines
Omid S. Tehrani, Anthony F. Shields
Journal of Nuclear Medicine Jun 2013, 54 (6) 903-912; DOI: 10.2967/jnumed.112.112201
Jump to section
Related Articles
Cited By...
- 18F-FLT PET/CT Adds Value to 18F-FDG PET/CT for Diagnosing Relapse After Definitive Radiotherapy in Patients with Lung Cancer: Results of a Prospective Clinical Trial
- Using Radiolabeled 3'-Deoxy-3'-18F-Fluorothymidine with PET to Monitor the Effect of Dexamethasone on Non-Small Cell Lung Cancer
- Sex as a Biologic Variable in Preclinical Imaging Research: Initial Observations with 18F-FLT
- Differential diagnosis of granulomatous lung disease: clues and pitfalls: Number 4 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza
- Preclinical Evidence That 3'-Deoxy-3'-[18F]Fluorothymidine PET Can Visualize Recovery of Hematopoiesis after Gemcitabine Chemotherapy
- Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients
- PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer
- 18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study
- 18F-FLT PET Evaluation of Radiation Response
- VEGF-Targeted Therapy Stably Modulates the Glycolytic Phenotype of Tumor Cells